In an opinion piece on TheScientist.com, Daniel W. Coyne writes, “Amgens incomplete report on an early major trial of epoetin misled the medical community about the anemia drugs risks and benefitsand helped make Amgen rich.”
In the book, “How We Do Harm,” Otis Brawley, MD, chief medical and scientific officer of the American Cancer Society, writes quite a bit about hemoglobin-building drugs. He discusses:
That book, in my opinion, may be the most powerful book about U.S. health care that I’ve ever read. Deborah Schoch of the California HealthCare Foundation’s Center for Health Reporting recently published a review of the book. She wrote:
“Brawleys book is a page-turner, rich with dramatic anecdotes. … It has the sharp edge of an investigative piece, exposing morally questionable clinical tests, drug companies in search of the next big money-maker, doctors granting wealthy patients what it labels irrational care.